Literature DB >> 7705883

Interleukin 8 and mast cell-generated tumor necrosis factor-alpha in neutrophil recruitment.

Y Zhang1, B F Ramos, B Jakschik, M P Baganoff, C L Deppeler, D M Meyer, D L Widomski, D J Fretland, M A Bolanowski.   

Abstract

In the reverse passive Arthus reaction in mouse skin and immune injury of mouse dermal basement membrane, neutrophil (PMN) infiltration in mast cell deficient WBB6F1-W/Wv (W/Wv) mice was only 40% of that in WBB6F1-(+)/+ (+/+) mice that had a normal mast cell repertoire. An anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody (mAb) decreased PMN infiltration by 35-80% in +/+ but not W/Wv mice. In addition, an anti-human interleukin-8 (IL-8) MAb, DM/C7, inhibited PMN infiltration of the skin induced by either intradermal administration of recombinant human IL-1 beta or immune complex deposition. In both models of immune complex injury, DM/C7 reduced PMN infiltration by 40-60% in +/+ mice but not W/Wv mice. PMN infiltration and the sensitivity of this infiltration to anti-TNF-alpha or DM/C7 MAb in W/Wv mice whose mast cell population had been restored was indistinguishable from the influx observed in +/+ mice. These data suggest that TNF-alpha, IL-8, and mast cells play a fundamental role in PMN recruitment following immune complex injury.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705883     DOI: 10.1007/bf01534385

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  42 in total

1.  Mast cells enhance the antibody-mediated injury of skin basement membrane in mice.

Authors:  Y Zhang; B F Ramos; B A Jakschik
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

2.  Synovial tissue macrophage as a source of the chemotactic cytokine IL-8.

Authors:  A E Koch; S L Kunkel; J C Burrows; H L Evanoff; G K Haines; R M Pope; R M Strieter
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

3.  Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells.

Authors:  F M Brennan; C O Zachariae; D Chantry; C G Larsen; M Turner; R N Maini; K Matsushima; M Feldmann
Journal:  Eur J Immunol       Date:  1990-09       Impact factor: 5.532

4.  Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ.

Authors:  R Gillitzer; R Berger; V Mielke; C Müller; K Wolff; G Stingl
Journal:  J Invest Dermatol       Date:  1991-07       Impact factor: 8.551

5.  Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin.

Authors:  M Sticherling; E Bornscheuer; J M Schröder; E Christophers
Journal:  J Invest Dermatol       Date:  1991-01       Impact factor: 8.551

6.  Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups.

Authors:  S C Donnelly; R M Strieter; S L Kunkel; A Walz; C R Robertson; D C Carter; I S Grant; A J Pollok; C Haslett
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

7.  Interleukin-8 as a mediator of sympathetic pain.

Authors:  F Q Cunha; B B Lorenzetti; S Poole; S H Ferreira
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

8.  Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis.

Authors:  M Seitz; B Dewald; N Gerber; M Baggiolini
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

9.  Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis.

Authors:  Y R Mahida; M Ceska; F Effenberger; L Kurlak; I Lindley; C J Hawkey
Journal:  Clin Sci (Lond)       Date:  1992-03       Impact factor: 6.124

10.  Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin.

Authors:  J R Gordon; S J Galli
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

View more
  8 in total

1.  Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.

Authors:  A J Strachan; I A Shiels; R C Reid; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Role of interleukin 8 on leucocyte-endothelial cell adhesion in intestinal inflammation.

Authors:  H Arndt; M A Bolanowski; D N Granger
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

3.  Induction of keratinocyte IL-8 expression and secretion by IgG autoantibodies as a novel mechanism of epidermal neutrophil recruitment in a pemphigus variant.

Authors:  E A O'Toole; L L Mak; J Guitart; D T Woodley; T Hashimoto; M Amagai; L S Chan
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

4.  Human intestinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis.

Authors:  K B Seydel; E Li; P E Swanson; S L Stanley
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

5.  TNF-alpha participates in an IgE-mediated cutaneous reaction in mast cell deficient, WBB6F1-W/Wv mice.

Authors:  H Nagai; T Sakurai; T Abe; A Matsuo; K Musoh; M Tsunematsu; N Inagaki
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

6.  Identification and characterization of rhesus macaque interleukin-8.

Authors:  J C Minnerly; M P Baganoff; C L Deppeler; B T Keller; S R Rapp; D L Widomski; D J Fretland; M A Bolanowski
Journal:  Inflammation       Date:  1995-06       Impact factor: 4.092

7.  Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?

Authors:  Melissa A Brown; Julianne K Hatfield
Journal:  Front Immunol       Date:  2012-06-07       Impact factor: 7.561

8.  Lyn is essential for fcgamma receptor III-mediated systemic anaphylaxis but not for the Arthus reaction.

Authors:  T Yuasa; M Ono; T Watanabe; T Takai
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.